Pfizer (PFE) Other Non-Current Assets (2009 - 2026)
Pfizer (PFE) posted quarterly Other Non-Current Assets of $9.8 billion for Q1 2026, little changed year-over-year from $9.8 billion in Q1 2025, and up 2.11% quarter-over-quarter from $9.6 billion in Q4 2025.
Pfizer (PFE) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Other Non-Current Assets for 18 consecutive years, with $9.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.11% year-over-year to $9.8 billion; the TTM figure through Mar 2026 stood at $9.8 billion (changed 0.11% YoY), while the FY2025 annual figure was $9.6 billion, down 1.89% from the prior year.
- Other Non-Current Assets grew to $9.8 billion in Q1 2026 per PFE's latest filing, from $9.6 billion in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $13.2 billion in Q4 2022 and bottomed at $7.7 billion in Q3 2022.
- Historically, Other Non-Current Assets has averaged $10.5 billion across 5 years, with a median of $9.8 billion in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 71.42% — and 2024, when it declined 21.28%.
- Pfizer's Other Non-Current Assets stood at $13.2 billion in 2022, then fell by 5.26% to $12.5 billion in 2023, then retreated by 21.28% to $9.8 billion in 2024, then retreated by 1.89% to $9.6 billion in 2025, then increased by 2.11% to $9.8 billion in 2026.
- Business Quant data shows PFE's Other Non-Current Assets at $9.8 billion in Q1 2026, $9.6 billion in Q4 2025, and $9.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 9.94 Bn |
| Mar 29, 2026 | 9.83 Bn |
| Dec 31, 2025 | 9.63 Bn |
| Sep 28, 2025 | 9.32 Bn |
| Jun 29, 2025 | 9.46 Bn |
| Mar 30, 2025 | 9.85 Bn |
| Dec 31, 2024 | 9.82 Bn |
| Sep 29, 2024 | 10.49 Bn |
| Jun 30, 2024 | 10.71 Bn |
| Mar 31, 2024 | 11.20 Bn |
| Dec 31, 2023 | 12.47 Bn |
| Jul 2, 2023 | 13.03 Bn |
| Apr 2, 2023 | 12.97 Bn |
| Dec 31, 2022 | 13.16 Bn |
| Jul 3, 2022 | 7.66 Bn |
| Apr 3, 2022 | 7.88 Bn |
| Dec 31, 2021 | 7.68 Bn |
| Oct 3, 2021 | 6.71 Bn |
| Jul 4, 2021 | 6.06 Bn |
| Apr 4, 2021 | 4.74 Bn |